Under the extended agreement, which now runs until June 2010, MorphoSys continues to grant OncoMed access to its proprietary antibody library HuCAL Gold for the use in the research and development of human therapeutic antibodies for the treatment of various cancers by targeting cancer stem cells. The extended agreement includes annual user fees to MorphoSys for OncoMed’s access to the HuCAL platform.
The two-year extension includes an option for OncoMed to develop and commercialize up to three additional HuCAL-derived therapeutic antibodies. In all cases MorphoSys stands to receive exclusive license fees, milestone payments, as well as royalties on end products.
Paul Hastings, CEO of OncoMed, said: “The HuCAL technology has proven to be an effective tool for generating these antibodies and we are pleased to be able to continue our productive relationship with MorphoSys.”